His supporters say that if anyone can pull off such an enterprise it is R. J. Kirk, whom they call an uncommon visionary and quick study, though he lacks formal training in science. When Mr. Kirk tells people, as he often does, that he is just a country lawyer, they know they’re about to get a schooling in biology or business, interlaced with references to history, philosophy and opera. “He has an astonishing grasp of science,” said Dr. Samuel Broder, a former director of the National Cancer Institute who now runs Intrexon’s health division. Dr. Broder recalled one instance in which it took him a day to understand the intricacies of a genetic disease. Mr. Kirk, after hearing Dr. Broder’s explanation, got it in five minutes. Even the hedge fund manager Thomas U. Barton, who made his mark as a skeptical short-seller, gushes. “He understands all businesses,” he said. Still, there are skeptics. It is hard to judge the strength of Intrexon’s core technology, known as UltraVector, which is a computerized system for putting together modular DNA pieces to make complex genetic circuits. The company, saying it wants to protect its trade secrets, has not published articles about it in scientific literature. Some start-up companies, not Intrexon, have taken the lead in the hot new genome editing technique called Crispr. The biggest criticism is that Intrexon keeps announcing new acquisitions and new collaborations, dozens of them in all. Yet no product made with the company’s technology has reached the market, and it is not clear when any will. “There’s a mixture here of spectacle and speculation,” said Jim Thomas of the nonprofit ETC Group, which says that synthetic biology needs to be more rigorously regulated. “What’s curious about this is the way in which they are putting together all these controversial and often failing one-trick companies and trying to wrap them up in a fancy synthetic biology front.”
After tests in Brazil by British , the Oxitec biotech company owned by Intrexon , showed a fall of 82% in the population of wild mosquitoes after the introduction of its genetically engineered mosquitoes whose offspring die before reaching adulthood, the Intrexon is "greatly expediting" the company's application for further testing in the Florida Keys and is planning to release a draft environmental assessment soon. Despite critics who question whether the technology is scalable to tackle the Florida epidemic, Intrexon is building a factory in Piracicaba , Brazil , to produce 60m male mosquitoes a week , enough to protect at least 300k people.